Optum Medical Care, PC

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Chronic lymphocytic leukaemia4 trials
• Lung cancer3 trials
• Follicular lymphoma2 trials
• Mantle cell lymphoma1 trial

Phase

• Phase 37 trials
• Phase 11 trial

Status

• Recruiting6 trials
• Active, not recruiting2 trials

Lead sponsor

• BeOne Medicines4 trials
• Bristol-Myers Squibb2 trials
• Carna Biosciences, Inc.1 trial
• Nuvalent Inc.1 trial

Running trials

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

  Contact: Jonathan Goldberg, Site 0909

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

  Contact: Jonathan Goldberg, Site 0214

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

  Contact: Jonathan S. Goldberg, M.D. (principal investigator)

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

  Contact: Study Director

• Recruiting

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· Phase 3· BeOne Medicines· Source

  Contact: Study Director

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

  NCT06073821· Phase 3· BeOne Medicines· Source

• Recruiting

  AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  NCT05602363· Phase 1· Carna Biosciences, Inc.· Source

  Contact: Jonathan Goldberg, MD

• Active, not recruiting

  A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  NCT05100862· Phase 3· BeOne Medicines· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia3 recruiting
• Lung cancer3 recruiting
• Follicular lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting